According to a recent meta-analysis, the beneficial off-target effects of early-life BCG vaccine could prevent atopic eczema. The meta-analysis included three randomized controlled trials involving 5655 children randomly assigned to either early-life intervention BCG Denmark vaccination (n = 2832) or no BCG (n = 2823).
The meta-analyses revealed that the BCG Denmark vaccine had a beneficial effect preventing eczema (risk ratio [RR], 0.89; 95% CI, 0.82-0.98). Subgroup analyses revealed that BCG was more beneficial in male children (RR, 0.84; 95% CI, 0.74-0.95) and children of two atopic parents (RR, 0.81; 95% CI, 0.68-0.97). The researchers concluded that the BCG Denmark vaccine delivered in early life leads to an 11% reduction in the risk for eczema with a greater effect for increasing predisposition.
Learn more about BCG immunotherapy.
This Rapid Review Quiz was excerpted and adapted from the Medscape articles: Flu Vaccination Associated With Reduced Stroke Risk, Haemophilus Influenzae Infections, Data Hint COVID-19 Vax May Improve Immunotherapy Efficacy in Some, Nasopharyngeal Cancer, Atrial Fibrillation, Dementia Pathology, and Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer Overview of BCG Immunotherapy.
Lead image: Rangpl/Dreamstime
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Rapid Review Quiz: Unusual Vaccine News - Medscape - Feb 13, 2023.